Category: SEC Filings

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 16, 2021, Willis Towers Watson Public Limited Company (“Willis Towers Watson”) announced that its Board of Directors has appointed Carl Hess as President of Willis Towers Watson, effective immediately, and to succeed John…

Read More “8-K Emp Changes Reg FD – WILLIS TOWERS WATSON PLC (0001140536) August 16” »

Item 2.02 Results of Operations and Financial Condition. On August 16, 2021, Global Self Storage, Inc. (the “Company”) reported its financial results for the period ended June 30, 2021. A copy of the Company’s earnings press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 7.01 Regulation FD Disclosure. The…

Read More “8-K Earnings Reg FD – Global Self Storage, Inc. (0001031235) August 16” »

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Effective on August 16, 2021, Aspen Group, Inc. (the “Company”) entered into an Employment Agreement with Matthew LaVay, who had been appointed as the Chief Financial Officer of the Company on July 8, 2021…

Read More “8-K Emp Changes – ASPEN GROUP, INC. (0001487198) August 16” »

Item 7.01. Regulation FD Disclosure. On August 16, 2021, Talos Energy Inc. (the “Company”) posted a new investor presentation on its website, www.talosenergy.com, that it plans to use in connection with the upcoming EnerCom Conference. A copy of the presentation can be reviewed at the Company’s website by first selecting “Investors,” then selecting the “Events…

Read More “8-K Reg FD – TALOS ENERGY INC. (0001724965) August 16” »

Item 2.02. Results of Operations and Financial Condition. Reviva Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on August 16, 2021, disclosing financial information and operating metrics for its fiscal quarter ended June 30, 2021 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this…

Read More “8-K Earnings Reg FD – REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) August 16” »

Item 8.01.Other Events.On August 16, 2021, 9 Meters Biopharma, Inc. announced a collaboration with the European Biomedical Research Institute of Salerno. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.Item 9.01.Financial Statements and Exhibits.(d) ExhibitsExhibit No.DescriptionExhibit 99.1Press Release dated August 16, 2021. SIGNATURES Pursuant to the…

Read More “8-K Other Events – 9 METERS BIOPHARMA, INC. (0001551986) August 16” »

Item 7.01. Regulation FD Disclosure. On August 16, 2021, the Chief Executive Officer of QuantumScape Corporation (the “Company”) posted information for investors via his Twitter account located at https://twitter.com/startupjag. The Company’s investor relations website is located at https://ir.quantumscape.com, its Company Twitter account is located at https://twitter.com/QuantumScapeCo, its investor relations Twitter account is located at https://twitter.com/QuantumScapeIR,…

Read More “8-K Reg FD – QuantumScape Corp (0001811414) August 16” »

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 16, 2021, Mersana Therapeutics, Inc. (the “Company”) announced that Michael Kaufman, Ph.D., will step down as the Company’s Chief Manufacturing Officer, effective immediately. Dr. Kaufman’s employment will continue through September 10, 2021 to…

Read More “8-K Emp Changes Reg FD – Mersana Therapeutics, Inc. (0001442836) August 16” »

Item 2.02.Results of Operations and Financial Condition. On August 16, 2021, NeuroBo Pharmaceuticals, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2021. A copy of the press release is furnished herewith as Exhibit 99.1. The information included herein and in Exhibit 99.1 shall not be deemed “filed”…

Read More “8-K Earnings – NeuroBo Pharmaceuticals, Inc. (0001638287) August 16” »

Item 2.02 Results of Operations and Financial Condition. Nemaura Medical Inc. (the “Company”) issued an earnings release on August 16, 2021 to announce its financial results for the three months ended June 30, 2021. A copy of the earnings release is furnished herewith as Exhibit 99.1. The information under this Item 2.02 is being furnished…

Read More “8-K Earnings Reg FD – Nemaura Medical Inc. (0001602078) August 16” »